Berlin Heals Holding AG

Berlin Heals GmbH, based in Switzerland, develops innovative medical devices aimed at treating systemic heart failure, specifically through its flagship C-MIC device. Berlin Heals GmbH specializes in cardiac implants, primarily the C-MIC device, which targets patients with systemic and refractory heart failure. The company was founded in 2014 in Zug, Switzerland. It has executed a total of 4 deals, with its most recent funding round occurring on February 18, 2025, where it raised CHF 7 million in venture funding.

The leadership team includes CEOs Johannes Mueller, Marko Bagaric, and Peter Goettel. Berlin Heals focuses on the C-MIC device, which is a revolutionary implant for patients experiencing systemic heart failure. This device delivers a continuous, minimal electrical direct current to the heart, promoting reverse remodeling of cardiac tissue. The C-MIC device meets a critical medical need where traditional treatments have failed.

It is primarily marketed to healthcare providers, particularly in European markets where clinical trials have taken place, and the company plans to expand into the U. S. market through an Early Feasibility Study following the successful completion of its pilot studies in 2020 and 2021. The revenue stream for Berlin Heals is mainly derived from the sales of the C-MIC device, which is sold directly to healthcare institutions specializing in cardiology.

The company's business model includes partnering with hospitals and clinics, who order the devices based on patient requirements. The pricing of the C-MIC device reflects its value in enhancing heart failure treatment and is designed to be compatible with healthcare budgeting limitations. Berlin Heals GmbH plans to leverage the CHF 7 million raised in February 2025 to further its research into the effectiveness and safety of its innovative cardiac treatments. The company is focused on expanding its market presence, particularly in the U.

S. and other regions, with the intention of launching additional products in the coming years. This strategic funding will support the ongoing development of the C-MIC device and its entry into new markets.